Quoin Pharmaceuticals Ltd
QNRX13.750USD
-0.450-3.17%
收盤 12/22, 16:00（美東）報價延遲15分鐘
283.06M總市值
虧損本益比TTM
關於 Quoin Pharmaceuticals Ltd 公司
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Quoin Pharmaceuticals Ltd簡介
公司代碼QNRX
公司名稱Quoin Pharmaceuticals Ltd
上市日期Nov 01, 1989
CEOMyers (Michael)
員工數量3
證券類型Depository Receipt
年結日Nov 01
公司地址23 Hata'as Street
城市KFAR SABA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編44425
電話97299741444
網址https://quoinpharma.com/
公司代碼QNRX
上市日期Nov 01, 1989
CEOMyers (Michael)
Quoin Pharmaceuticals Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
440.00
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Yali Sheffi
Mr. Yali Sheffi
Independent External Director
Independent External Director
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
440.00
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 12月19日 週五
更新時間: 12月19日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Ikarian Capital LLC
25.21%
Stonepine Capital Management, LLC
7.00%
Resolute Capital Asset Partners LLC
5.96%
Myers (Michael)
2.05%
Carter (Denise P)
2.05%
其他
57.72%
持股股東
持股股東
佔比
Ikarian Capital LLC
25.21%
Stonepine Capital Management, LLC
7.00%
Resolute Capital Asset Partners LLC
5.96%
Myers (Michael)
2.05%
Carter (Denise P)
2.05%
其他
57.72%
股東類型
持股股東
佔比
Hedge Fund
25.21%
Investment Advisor/Hedge Fund
7.03%
Individual Investor
6.82%
Investment Advisor
6.10%
其他
54.83%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
28
2.54K
0.30%
-52.73K
2025Q2
34
51.05K
8.68%
-35.06K
2025Q1
35
78.22K
9.34%
-7.90K
2024Q4
33
2.93M
35.77%
+2.56M
2024Q3
29
288.95K
5.54%
-93.09K
2024Q2
30
301.96K
12.37%
-13.30K
2024Q1
28
276.13K
11.96%
+132.88K
2023Q4
28
104.03K
10.54%
-33.36K
2023Q3
27
83.72K
8.48%
+6.49K
2023Q2
28
91.62K
18.66%
+37.20K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Ikarian Capital LLC
--
0%
-7.86K
-100.00%
Mar 31, 2025
Myers (Michael)
17.22K
0.08%
--
--
Jul 16, 2025
Carter (Denise P)
17.22K
0.08%
-1.00
-0.01%
Jul 16, 2025
Langer (Dennis H)
1.00
0%
-1.00
-50.00%
Jul 16, 2025
Dunn (Gordon)
4.32K
0.02%
--
--
Jul 16, 2025
Culverwell (Anthony James)
2.87K
0.01%
--
--
Jul 16, 2025
Rhumbline Advisers Ltd. Partnership
1.24K
0.01%
+49.00
+4.11%
Jun 30, 2025
Lawlor (Sally Bridget)
440.00
0%
+440.00
--
Aug 18, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 26, 2025
Merger
35→1
Mar 26, 2025
Merger
20→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
公告日期
類型
比率
Mar 26, 2025
Merger
35→1
Mar 26, 2025
Merger
20→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
查看更多
常見問題
Quoin Pharmaceuticals Ltd的前五大股東是誰？
Quoin Pharmaceuticals Ltd的前五大股東如下：
Ikarian Capital LLC持有股份：0.00佔總股份比例：0.00%。
Myers (Michael)持有股份：17.22K佔總股份比例：0.08%。
Carter (Denise P)持有股份：17.22K佔總股份比例：0.08%。
Langer (Dennis H)持有股份：1.00佔總股份比例：0.00%。
Dunn (Gordon)持有股份：4.32K佔總股份比例：0.02%。
Ikarian Capital LLC持有股份：0.00佔總股份比例：0.00%。
Myers (Michael)持有股份：17.22K佔總股份比例：0.08%。
Carter (Denise P)持有股份：17.22K佔總股份比例：0.08%。
Langer (Dennis H)持有股份：1.00佔總股份比例：0.00%。
Dunn (Gordon)持有股份：4.32K佔總股份比例：0.02%。
Quoin Pharmaceuticals Ltd的前三大股東類型是什麼？
Quoin Pharmaceuticals Ltd 的前三大股東類型分別是：
Ikarian Capital LLC
Stonepine Capital Management, LLC
Resolute Capital Asset Partners LLC
Ikarian Capital LLC
Stonepine Capital Management, LLC
Resolute Capital Asset Partners LLC
有多少機構持有Quoin Pharmaceuticals Ltd(QNRX)的股份？
截至2025Q3，共有28家機構持有Quoin Pharmaceuticals Ltd的股份，合計持有的股份價值約為2.54K，占公司總股份的0.30% 。與2025Q2相比，機構持股有所增加，增幅為-8.38%。
哪個業務部門對Quoin Pharmaceuticals Ltd的收入貢獻最大？
在--，--業務部門對Quoin Pharmaceuticals Ltd的收入貢獻最大，創收--，占總收入的--% 。
